Brief: Ironwood Pharmaceuticals Inc - HHS Releases Maximum Fair Price For Linzess - SEC Filing
26/11/2025 12:03
Nov 26 (Reuters) - SEC Filing: IRONWOOD PHARMACEUTICALS INC - HHS RELEASES MAXIMUM FAIR PRICE FOR LINZESS - SEC FILING IRONWOOD PHARMACEUTICALS INC - MFP FOR LINZESS SET AT $136 FOR 30-DAY SUPPLY - SEC FILING IRONWOOD PHARMACEUTICALS INC: REVISED MFP FOR LINZESS IS IN LINE WITH EXPECTATIONS OF CO Source text: [ID:n0001104659-25-116217] Further company coverage: IRWD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation